Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

l. One subject did not complete the trial due to personal reasons and one other subject did not complete the trial due to a serious adverse event, cholecystitis (gall stones), which was judged not related to the study drug.

Based on these important findings, the Company now plans to adjust its future dosing. Expanded Phase 2 planning is moving forward to include Phase 2 IVUS trials, a Phase 2 dosing trial and a Phase 2 combination statin trial. The IVUS Steering Committee is chaired by Dr. Steven Nissen, Chairman of the Cleveland Clinic Department of Cardiovascular Medicine, and the principal investigator is Dr. Stephen Nicholls, Medical Director of Intravascular Ultrasound at Cleveland Clinic.

"The results we have observed in our second clinical trial illustrate an important emerging pattern of predictability. To date 162 human subjects have received RVX-208 which has consistently demonstrated itself to be a well tolerated and safe therapeutic," stated Dr. Jan Johansson Senior Vice President of Medical Affairs at Resverlogix. "It is important to note that in addition to the increases in ApoA-I and HDL, we also saw very pronounced increases in alpha-1 HDL, another important marker for CVD risk. The landmark Framingham Offspring Study clearly illustrated that among HDL and LDL, alpha-1 HDL was a more critically important marker for CVD protection," Dr. Johansson added.

Developing small molecules that increase ApoA-I would satisfy a huge unmet medical need because CVD treatment with statins, the current standard of care, only stabilizes atherosclerosis and reduces cardiovascular risk by 30%. A recent cost-benefit pharmacoeconomic analysis of ApoA-I therapy for CVD estimated that a 1% and 5% regression of atherosclerosis would save the U.S. health care system and employers between US $22.9 billion and US $76.8 billion annually over and above statin therapy. The analysis assumes ApoA-I therapy will be
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... MDV-Mohr Davidow Ventures, a,leading Silicon Valley venture capital ... Dan Riskin to the firm as Executive-in-Residence and,Entrepreneur-in-Residence, ... provide healthcare providers and consumers more effective,ways to ... diagnosis to the,treatment of disease. , ...
... Switzerland and BANGALORE, India, November 20 ... development,specialist that focuses on serious medical ... Technologies Ltd (Aurigene), a,Bangalore-based fully integrated, ... peptide drug discovery and development from ...
... Nov. 19 Serica Technologies, Inc., a,growth-stage ... tissue regeneration, today announced that it has ... standards,required for medical device manufacturers. ISO certification ... regulatory bodies worldwide as proof of an,effective ...
Cached Biology Technology:MDV Expands Team Pursuing Advances in Personalized Medicine 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 3Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 2Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 3Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing 4
(Date:4/15/2014)... at UC San Diego have succeeded in visualizing ... responsible for growth and resistance to drought. The ... to determine how the hormone helps plants respond ... the continuing increase in the atmosphere,s carbon dioxide, ... appears in the April 15 issue of the ...
(Date:4/15/2014)... New Zealand,s pastoral landscapes are some of the loveliest ... threat. Many of the country,s pasture soils have become ... metal, which is then eaten by the cattle and ... to New Zealand; cadmium-enriched soils being reported worldwide. , ... unsafe levels in meat and dairy products, human health ...
(Date:4/15/2014)... 2050, deforestation could cause temperatures in the Congo ... would intensify warming caused by greenhouse gases by ... the University of Leuven, Belgium. , Explosive population ... destruction of tropical rainforests in Central Africa. A ... examined how these practices will affect longer-term temperatures ...
Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2Study: Deforestation could intensify climate change in Congo Basin by half 2
... 2011) Researchers looking to find a root cause for ... a novel investigative approach that borders on science fiction as ... the nation,s No. 1 killer. The National Institutes of ... Scripps Translational Science Institute (STSI) of San Diego and Sangamo ...
... wide variety of new cut flower cultivars and species ... University and the Association of Specialty Cut Flower Growers. ... United States and Canada, provides valuable production and marketing ... team from North Carolina State University undertook a multiyear ...
... Stephane Len, both researchers at the IRMES (Institut de ... France), have published their findings in Age , ... the evolution of performances in elite athletes and chess ... developed by the laboratory, and suggests that changes in ...
Cached Biology News:Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 2Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 3Scripps awarded $7.9 million NIH grant for research to find root cause of heart attack 4Extending the vase life of cut flowers: Pre-treatments and preservatives studied 2Evolution of sport performances follows a physiological law 2
In plasmid or lambda vector. Please inquire for more details!...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
... SARA ( Abpromise for all tested ... peptide: PVPKEMEQPV QTEEEDVELP conjugated to KLH, corresponding ... (Drosophila melanogaster) SARA. Conserved sequence unique ... ID: 9372 Swiss ...
Biology Products: